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Abstract We investigated the effect of two peptide nucleic acids
(PNAs), which are complementary to the RNA component of
human telomerase, on the catalytic activity of the enzyme. PNAs
induced a dose-dependent reduction of telomerase activity in cell
extracts from human melanoma cell lines and surgical specimens.
To down-regulate telomerase in intact cells, we generated a
chimeric molecule synthesized by coupling the 13-mer PNA to
the Antennapedia peptide. The PNA construct induced a dose-
and time-dependent inhibition of telomerase activity. However, a
20-day exposure to the PNA construct only caused a slight
increase in melanoma cell doubling time and failed to induce any
telomere shortening.
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1. Introduction
Human telomerase is a ribonucleoprotein enzyme complex
that compensates for telomeric sequence loss, due to the end
replication problem [1] by adding 5P-TTAGGG-3P repeats at
the end of linear chromosomes [2]. The essential role of telo-
merase is to ensure chromosome integrity [3]. Its almost ubiq-
uitous expression in human tumors, and not in somatic cells
[4], has supported the hypothesis that the enzyme is involved
in cellular immortality and carcinogenesis. The notion that
telomere maintenance is essential for the formation of human
tumor cells has recently been supported by the ¢ndings of
Hahn et al. [5], who demonstrated that ectopic expression of
the telomerase catalytic subunit in combination with two on-
cogenes (SV 40 large-T and H-ras) resulted in direct tumori-
genic conversion of normal human epithelial and ¢broblast
cells.
Telomerase is considered as a potential candidate for new
targeted therapies with putatively low side e¡ects. In fact,
human germ and stem cells that also express telomerase
have long telomeres and would be a¡ected by a telomerase
inhibitor later than cancer cells.
The RNA component of human telomerase acts as a tem-
plate for the addition of new telomeric repeats by the reverse
transcriptase domain [6] of the enzyme. The inherent accessi-
bility to incoming nucleic acids makes telomerase an ideal
target for antisense oligonucleotides. Inhibition of telomerase
activity by conventional DNA oligomers [7^9] and phosphor-
othioate-modi¢ed DNA [10] has been reported. However, the
poor sequence selectivity observed with such compounds [10]
has lead to the search for second generation oligonucleotides
able to bind complementary sequences with very high a⁄nity.
In this context, an e⁄cient inhibition of telomerase activity
has been obtained by 2P-O-methyl-RNAs [11] and peptide
nucleic acids (PNAs) [10]. Speci¢cally, PNAs are DNA
mimics in which the sugar-phosphate backbone has been re-
placed by a backbone based on amino acids. The uncharged
nature of the PNA internucleotide linkage increases the stabil-
ity of the PNA/DNA (or PNA/RNA) duplex and a¡ords
greater resistance to protease and nuclease [12^14] than un-
modi¢ed DNA oligomers.
Due to the ine⁄cient cellular uptake of oligomers, methods
for enhancing their intracellular delivery have been developed,
mainly through the use of cationic lipids [15]. PNAs are not
taken up spontaneously by cells. Moreover, because of their
neutral backbone, PNAs lack the ability to interact with cat-
ionic lipids. Cell-penetrating PNA constructs have been gen-
erated [16] by coupling PNA oligomers with cellular trans-
porter peptides, which are able to enter cells in an energy-
and receptor-independent manner. The 27-amino acid long
peptide transportan [16] and the 16-amino acid long peptide
corresponding to the third helix of the DNA binding domain
of Antennapedia have been used. Speci¢cally, the homeodo-
main of the transcription factor Antennapedia is able to trans-
locate through biological membranes, and such an internal-
ization does not depend on classical endocytosis [17].
In the present study, we evaluated the inhibitory e¡ect on
telomerase activity of 11-mer and 13-mer PNAs complemen-
tary to the template region of human telomerase in extracts
from human melanoma cell lines and surgical specimens. We
also compared inhibition by the 13-mer PNA with that pro-
duced by a phosphorothioate oligodeoxynucleotide of analo-
gous sequence. Moreover, with the aim to down-regulate
telomerase activity in intact cells, a chimeric molecule,
synthesized by coupling the 13-mer PNA to the Antennapedia
cell-penetrating peptide, was delivered to growing melanoma
cells and evaluated for its potential anti-telomerase activity as
well as for its interference with cell proliferation. The possi-
bility to inhibit melanoma cell growth through a negative
interference with telomerase appears reasonable since telomer-
ase reactivation has been detected in a high percentage of
melanoma lesions [18]. Moreover, melanoma is highly refrac-
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tory to all conventional anti-cancer treatments and thus rep-
resents a good model to test innovative therapeutic ap-
proaches.
2. Materials and methods
2.1. Synthesis of oligomers, peptide and PNA constructs
PNA monomers were obtained from PerSeptive Biosystems (Fra-
mingham, MA, USA). 11-mer (5P-GGGTTAGACAA-3P) and 13-mer
(5P-TAGGGTTAGACAA-3P) PNA oligomers were synthesized using
the f-moc peptide chemistry according to protocols developed by the
manufacturer (PerSeptive). A non-complementary 13-mer (5P-TGT-
AAGGACTAG) PNA was also synthesized. The phosphorothioate
oligodeoxynucleotide (5P-TAGGGTTAGACAA-3P) was synthesized
using thioate chemistry and gel-¢ltered with a Sephadex column.
The Antennapedia peptide (QIKIWFQNRRMKWKK, pAntennape-
dia) was assembled using the f-moc strategy of solid phase peptide
synthesis. During the automated synthesis of 13-mer PNA, and with
the ¢nal purpose to conjugate it with the Antennapedia peptide, two
linkers were added to the amino-terminus of the PNA. Biotinylated
13-mer PNA and biotinylated Antennapedia peptide were also pre-
pared. The scheme of synthesis of the cell-penetrating PNA construct
was the following: Cys-pAntennapedia+Cys-2 linkers-13-mer PNA
(or biotinyl-Cys-2 linkers-13-mer PNA)CpAntennapedia-Cys-S-S-
Cys-2 linkers-13-mer PNA (or pAntennapedia-Cys-S-S-(biotinyl)-
Cys-2 linkers-13-mer PNA).
Oligomers, peptides and PNA constructs were puri¢ed by high-per-
formance liquid chromatography and analyzed by mass spectrometry.
2.2. Tumor material
Two cell lines (JR8 and M14) and four surgical specimens of hu-
man cutaneous melanoma were used in the study. The biological
characteristics of the cell lines have previously been reported [19].
JR8 and M14 cells were maintained in the logarithmic growth phase
at 37‡C in a 5% CO2 humidi¢ed atmosphere using RPMI 1640 (Bio-
whittaker, Vervires, Belgium) supplemented with 10% fetal calf serum,
2 mM L-glutamine and 0.25% gentamicin.
2.3. Telomerase activity detection assay
Cell extracts were obtained as previously described [20]. Telomerase
activity was measured by the telomeric repeat ampli¢cation protocol
(TRAP) [4]. After extension of the substrate by telomerase, the prod-
ucts were ampli¢ed by PCR in the presence of 32P-end-labeled TS
primer and resolved in 10% polyacrylamide gels. Each reaction prod-
uct was ampli¢ed in the presence of a 36-bp internal TRAP assay
standard (ITAS), and each sample extract was tested for RNase sen-
sitivity. A TSR8 quantitation standard (which serves as a standard to
estimate the amount of product extended by telomerase in a given
extract) was included for each set of TRAP assays. Quantitative anal-
ysis was performed with the Image-QuanT software (Molecular Dy-
namics, Sunnyvale, CA, USA), which allowed densitometric evalua-
tion of the digitized image. Telomerase activity was quanti¢ed by
measuring the signal of telomerase ladder bands, and the relative
telomerase activity was calculated as the ratio to the internal standard
using the following formula:
relative telomerase activity : X3X 0=CUR3R0=Cr31
where X is the untreated sample, X0 is the RNase-treated sample, C is
the internal control of untreated samples, Cr is the internal control of
TSR8, R is the TSR8 quantitation control and R0 is the negative
control.
The e¡ect of the PNA and phosphothioate oligomers as well as of
the cell-penetrating PNA construct on telomerase was expressed as the
percentage inhibition of enzyme activity in samples exposed to indi-
vidual oligomers compared to untreated controls. The extent of inhi-
bition as a function of the oligomer concentration was plotted, and
the graphs were utilized to derive the IC50 values.
2.4. Immuno£uorescence assay
JR8 cells were exposed to the biotinylated PNA construct (10^50
WM) for 1 h or 4 h at 37‡C. After incubation, the cells were extensively
washed with ice-cold phosphate-bu¡ered saline (PBS) and ¢xed in
70% ethanol for 15 min at 4‡C, and non-speci¢c binding was blocked
with 5% bovine serum albumin. Control cells (grown in control me-
dium without the biotinylated PNA construct) were processed in par-
allel. The internalized biotinylated PNA construct was detected by
£uorescence microscopy using a mouse monoclonal antibody anti-
biotin (1:200) (Vector Laboratories, Burlingame, CA, USA) and a
secondary anti-mouse IgG^FITC conjugate (1:50) (Sigma Chemical
Co., St. Louis, MO, USA).
2.5. Cell proliferation assay
After harvesting in the logarithmic growth phase, cells were seeded
in 6-well plates. Cell-penetrating PNA construct (10^50 WM) was
added to the culture medium, and cells were incubated at 37‡C in a
5% CO2 humidi¢ed atmosphere for 6 or 20 days. At the end of treat-
ment, cells were washed with PBS, then trypsinized and counted in a
particle counter (Coulter Counter, Coulter Electronics, Luton, UK).
The results were expressed as the number of cells in treated samples
compared to control samples. For each experimental point, a sample
of cells was stained with propidium iodide and analyzed under £uo-
rescence microscopy to evaluate the presence of cells with the charac-
teristic nuclear morphology of apoptosis.
2.6. Telomere length measurement
Total DNA was isolated using DNAzol (Life Technologies, Gai-
thersburg, MD, USA), digested with 40 U of HinfI, and then electro-
phoresed on 0.8% agarose gels. Following electrophoresis, gels were
denatured, neutralized, transferred to a nylon membrane and then
cross-linked with UV light. The membrane was hybridized with
a 5P-end [Q-32P]dATP-labeled telomeric oligonucleotide probe
(TTAGGG)4 by a standard protocol. Filters were autoradiographed
(Hyper¢lm-MP; Amersham) with an intensifying screen at 380‡C for
12^24 h. Autoradiographs were scanned (ScanJet IIcx/T; Hewlett
Packard) and the peak TRF length was calculated as previously re-
ported [21].
3. Results
Exposure of melanoma cell extracts to di¡erent concentra-
tions (1^1000 nM) of 11-mer and 13-mer PNAs for 30 min at
37‡C induced a dose-dependent inhibition of telomerase activ-
ity, with a progressive decline of TRAP signals starting from
Table 1
IC50 values for the inhibition of telomerase activity by PNA and PS oligomers in cell extracts and permeabilized cells
IC50 (nM)
11-mer PNA 13-mer PNA PS
Cell extracts
Cell lines: JR8 67 þ 6 35 þ 4 500 þ 15
M14 95 þ 8 70 þ 7 1000 þ 30
Tumors: ML1342 n.d. 79 þ 6 n.d.
ML1256 n.d. 77 þ 7 n.d.
ML1258 n.d. 100 þ 6 n.d.
ML1259 n.d. 85 þ 4 n.d.
Permeabilized cells
Cell line: JR8 490 þ 29 360 þ 23 s 1000
Data represent mean values þ S.E.M. from three independent experiments. PS, phosphorothioate oligodeoxynucleotide. n.d., not determined.
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the concentration of 10 nM. Results of a representative ex-
periment on JR8 cell extract are shown in Fig. 1A. The 13-
mer PNA was more e⁄cient than the 11-mer PNA in inhibit-
ing the enzyme (Fig. 1B), as demonstrated by the lower IC50
values (Table 1). Such a ¢nding was particularly evident in the
JR8 cell line (P6 0.05, Student’s t-test for paired samples).
No inhibition of telomerase activity was observed when cell
extracts were incubated in the presence of the non-comple-
mentary PNA. The relative e⁄ciency of inhibition by the
13-mer PNA was then compared to that by a phosphoro-
thioate oligodeoxynucleotide of analogous sequence (Fig.
1A). A substantially lower e¡ect of the phosphorothioate olig-
omer (P6 0.001) was observed (Fig. 1B and Table 1).
A dose-dependent inhibition of telomerase activity by the
13-mer PNA was also con¢rmed in extracts obtained from
four melanoma surgical specimens (Fig. 2A,B). The 13-mer
PNA IC50 values obtained in the di¡erent tumors ranged
from 77 to 100 nM (Table 1). When applied to mildly per-
Fig. 1. (A) TRAP assay showing inhibition of telomerase activity by di¡erent concentrations of PNA and phosphorothioate (PS) oligomers in
JR8 melanoma cell extract. The lane denoted Lysis bu¡er represents a negative control to which no cell extract was added. The lane denoted
+RNase represents a negative control containing the cell extract pretreated with RNase. The location of the internal ampli¢cation standard
(ITAS) is noted. (B) Quantitation of PNA and PS oligomer-mediated telomerase inhibition in JR8 and M14 melanoma cell extracts. The e¡ect
of inhibitors on telomerase is expressed as the percentage inhibition of enzyme activity compared to control. The data represent mean values þ
S.E.M. from three independent experiments for each cell line.
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meabilized JR8 melanoma cells, PNAs continued to inhibit
telomerase activity but with IC50 values markedly higher
than those required for inhibition in puri¢ed extracts (Table
1). Again, under such experimental conditions, the 13-mer
PNA was more e⁄cient than the 11-mer PNA as a telomerase
inhibitor. As regards the phosphorothioate oligomer, the IC50
for the compound was not reached at any of the tested con-
centrations (Table 1).
For intracellular delivery to intact, growing JR8 melanoma
cells, the 13-mer PNA was coupled to the Antennapedia cell-
penetrating peptide. Biotin labeling of the PNA construct was
instrumental to detect the compounds within cells by using an
immuno£uorescence method. As shown in Fig. 3, after a 4-h
exposure, the biotinylated PNA construct was present and
distributed homogeneously within the cells. Moreover, an in-
crease in £uorescence signal was observed by increasing the
time of exposure and the concentration of the biotinylated
PNA construct (Fig. 3A,B). Absence of a signi¢cant £uores-
cence signal after exposure of cells to the biotinylated 13-mer
PNA indicated a lack of internalization of the molecule (data
not shown), whereas a strong signal was observed after a 4-h
exposure to 50 WM biotinylated Antennapedia peptide (Fig.
3C). Exposure of JR8 cells to di¡erent concentrations (10^50
WM) of the PNA construct for 4 and 8 h induced a negligible
e¡ect on telomerase activity (data not shown). Conversely, a
dose- and time-dependent inhibition of enzyme activity was
observed after longer exposure times (Fig. 4A,B). Speci¢cally,
the mean IC50 value obtained for a 24-h treatment was 36 þ 6
WM, and it dropped to 7.5 þ 4 WM when the exposure time
was prolonged to 144 h. No interference with telomerase ac-
tivity was observed after exposure of cells to concentrations of
up to 50 WM of the Antennapedia peptide for 24^144 h (Fig.
5) or of the biotinylated 13-mer PNA for 144 h (Fig. 6).
Next we assessed the e¡ect of treatment with the cell-pen-
etrating PNA construct (10^50 WM) on the proliferation of
JR8 cells. After a 144-h exposure, a negligible e¡ect on cell
growth was induced by the PNA construct, even in the pres-
ence of a markedly reduced telomerase activity (Fig. 4). In
fact, the reduction of cell number in treated samples com-
pared to controls ranged from 1% to 8% for the di¡erent
concentrations of the PNA construct. Moreover, £uorescence
microscopy analysis of cells stained with propidium iodide
failed to evidence cells with an apoptotic nuclear morphology.
In parallel, the analysis of telomere length performed by
Southern blot hybridization did not show any telomere short-
ening in cells treated with the PNA construct with respect to
control cells (Fig. 7). When the treatment with the PNA con-
struct (50 WM) was prolonged for 20 days, cells were still able
to proliferate even though they showed a signi¢cantly
(P6 0.01) longer doubling time than that of untreated control
cells (30.3 þ 0.97 h vs. 24.0 þ 1.08 h). Moreover, £uorescence
microscopy analysis revealed the presence of a small but sig-
ni¢cant percentage of apoptotic cells in treated samples
(5.8 þ 1.35% of the overall cell population). However, even
at this time point, no telomere shortening was observed in
treated cells compared to controls (data not shown).
4. Discussion
Telomerase is potentially an important therapeutic target in
the treatment of human malignancies. In fact, the di¡erential
expression of telomerase in normal and tumor cells suggests
Fig. 2. (A) Inhibition of telomerase activity by di¡erent concentra-
tions of 13-mer PNA in an extract from a melanoma surgical speci-
men. The lane denoted Lysis bu¡er represents a negative control to
which no cell extract was added. The lane denoted +RNase repre-
sents a negative control containing the cell extract pretreated with
RNase. The location of the internal ampli¢cation standard (ITAS)
is noted. (B) Quantitation of 13-mer PNA-mediated telomerase inhi-
bition in cell extract from four melanoma surgical specimens. The
e¡ect of 13-mer PNA on telomerase is expressed as the percentage
inhibition of enzyme activity compared to control. The data repre-
sent mean values þ S.E.M. from three replicated samples for each
tumor specimen.
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that telomerase inhibitors may have relative speci¢city for
malignant cells. Since telomerase utilizes an 11-base sequence
belonging to its RNA component to add telomeric repeats to
the end of chromosomes, one strategy for inhibiting enzyme
activity may be physical blockage of the RNA template.
Moreover, due to its necessary accessibility to incoming nu-
cleic acids, telomerase should be highly susceptible to oligo-
nucleotide binding.
In the present study, we evaluated the ability of two PNAs,
an 11-mer and a 13-mer DNA analogues designed to cover
the template and the 5P-proximal region of human telomerase,
to inhibit enzyme activity in extracts of cutaneous melanoma
cell lines. PNAs lowered telomerase activity in a dose-depen-
dent fashion, with IC50 values in the nanomolar range. Such
results are in agreement with previous ¢ndings of Norton et
al. [10], who demonstrated a PNA-mediated inhibition of te-
lomerase activity in cell extracts of a human immortal breast
epithelial cell line. Moreover, in a direct comparison, we ob-
served that the 13-PNA was more potent in inhibiting telo-
merase activity than a phosphorothioate oligodeoxynucleotide
of analogous sequence, thus supporting evidence of a higher
a⁄nity and selectivity of PNA through base pairing and not
electrostatic interactions for its target RNA [22]. An inhibi-
tory activity by the 13-mer PNA comparable to that observed
on melanoma cell line extracts was also recorded on cell ex-
tracts directly obtained from four melanoma surgical speci-
mens. Moreover, PNAs continued to inhibit telomerase activ-
ity in mildly permeabilized melanoma cells, although at
concentrations higher than those required in cell extracts.
PNAs are very potent molecules in vitro but they are poorly
transported across cell membranes [23^25], even though it has
recently been shown that naked PNAs are taken up by human
myoblasts [26]. However, in order to increase PNA uptake,
methods for their intracellular delivery have been developed,
mainly through conjugation with transport peptides. In par-
ticular, it has been reported that a bioconjugate, generated by
coupling a PNA antisense for the translation initiation region
of prepro-oxytocin mRNA with a retro^inverso delivery pep-
tide, was e⁄ciently internalized by cerebral cortex neurons
and depressed the amount of prepro-oxytocin message in
the cells [27]. Moreover, PNAs directed against inducible ni-
tric oxide synthase mRNA, and covalently linked to a hydro-
phobic peptide moiety, were successfully internalized in mouse
macrophages and induced a marked decrease in the catalytic
activity of the target enzyme [28]. Again, a 21-mer PNA com-
plementary to the human galanin receptor type 1 mRNA,
coupled to cellular transport peptides transportan or Anten-
napedia, was e⁄ciently taken up by Bowes human melanoma
cells, where it blocked the expression of galanin receptors [29].
By following such a strategy, and with the ¢nal aim to
down-regulate telomerase activity in growing melanoma cells,
we generated a chimeric molecule by coupling the 13-mer
PNA (which was selected as the best inhibitor of telomerase
in melanoma cell extracts and mildly permeabilized cells) with
the delivery peptide Antennapedia. The cysteine-containing
transport peptide was linked by a disul¢de bond to cysteine
linker-extended PNA. The disul¢de bond is thought to be
quickly reduced in the intracellular milieu, leading to the dis-
Fig. 3. Intracellular localization of the biotinylated PNA construct and biotinylated Antennapedia peptide in JR8 melanoma cells visualized by
immuno£uorescence. Cells were exposed to 10 WM of the biotinylated PNA construct for 1 h at 37‡C (A), to 50 WM of the biotinylated PNA
construct for 4 h at 37‡C (B), or to 50 WM of the biotinylated Antennapedia peptide for 4 h at 37‡C (C).
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sociation of the PNA from the carrier peptide, thereby per-
mitting PNA to associate with target RNA. However, the
PNA was extended with two linkers, in order to space out
the internalization peptide from the telomerase RNA template
after PNA binding in the case of a lack of disul¢de bond
reduction.
An inhibition of telomerase activity was observed in intact
melanoma cells exposed to the cell-penetrating PNA con-
struct, thus indicating that the chimeric molecule was taken
up by cells and that the PNA was able to speci¢cally interact
with its complementary RNA sequence. Internalization of the
PNA construct was also con¢rmed by £uorescence microsco-
py analysis using a biotinylated chimeric molecule. However,
the inhibitory e¡ect on telomerase activity was only appreci-
able at PNA concentrations much higher than those required
to induce telomerase inhibition in extracts and for exposure
times of at least 24 h. Such a di¡erence could be related to
multiple factors including the e⁄ciency of PNA construct in-
ternalization as well as the inaccessibility of target RNA due
to its subcellular compartmentalization and sequestration.
The inhibition of telomerase activity in cells treated with the
PNA construct was not re£ected by a signi¢cant decline in
Fig. 4. (A) Inhibition of telomerase activity after exposure of JR8 growing cells to di¡erent concentrations of the cell-penetrating PNA con-
struct for di¡erent intervals. The lane denoted Lysis bu¡er represents a negative control to which no cell extract was added. The lane denoted
+RNase represents a negative control containing the cell extract pretreated with RNase. The location of the internal ampli¢cation standard
(ITAS) is noted. (B) Quantitation of telomerase inhibition in JR8 cells after exposure to di¡erent concentrations of the cell-penetrating PNA
construct for di¡erent intervals. The e¡ect of the cell-penetrating PNA construct on telomerase is expressed as the percentage inhibition of en-
zyme activity compared to control. The data represent mean values þ S.E.M. from three independent experiments.
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proliferation. In fact, after 20 days of continuous treatment
with the PNA construct, JR8 melanoma cells were still able to
proliferate although they showed a longer doubling time than
that of control cells. Moreover, after a long-term exposure to
the PNA construct, we observed the presence of a small but
signi¢cant percentage of cells with a nuclear apoptotic mor-
phology, in agreement with previous reports indicating apo-
ptosis as one of the possible pathways induced by telomerase
inhibitors [30].
In testing telomerase inhibitors, the kinetics of cell killing
are di⁄cult to predict. In fact, anti-telomerase agents might
not have an immediate cytotoxic e¡ect because cells would
theoretically need to divide until their telomeres became crit-
ically short before succumbing to chromosomal instability.
Such a hypothesis implies the opportunity to deliver telomer-
ase inhibitors chronically and suggests that such inhibitors
might be most e¡ective in the setting of minimal residual
disease.
In PNA-treated cells, we failed to observe any shortening of
telomere length. However, it should be emphasized that in the
cells, telomerase activity was markedly reduced but not com-
pletely abrogated. The lack of telomere shortening might ten-
tatively be explained by the emergence of resistant cells
through the activation of alternative lengthening of telomeres
(ALT) mechanisms, which are responsible for the mainte-
nance of telomeres and have been demonstrated to be present
in a few tumors [31], even though our PNA-treated cells did
not show the very long and heterogeneous telomeres typical of
ALT cells [31]. Moreover, we have previously reported that, in
the same melanoma cell system, the inhibition of telomerase
activity by a hammerhead ribozyme targeting the RNA com-
ponent of telomerase did not result in any telomere shortening
[32]. Similarly, other attempts aimed to inhibit telomerase
through the interference with its RNA template did not dem-
onstrate telomere shortening [30] or cell growth arrest [33].
Overall, our results suggest that PNA oligomers, which are
directed against the RNA template of telomerase, represent a
new and potentially powerful method of speci¢cally a¡ecting
enzyme activity in growing cells. Although PNAs have major
advantages over other nucleotide analogues in terms of bind-
ing a⁄nity, chemical stability and resistance to nucleases, ef-
¢cient strategies for their intracellular delivery must be devel-
oped before PNAs can progress toward therapeutic use.
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Fig. 5. Telomerase activity of JR8 growing cells after exposure to
50 WM of the Antennapedia peptide for di¡erent intervals: 24 h
(lane a), 48 h (lane b), 96 h (lane c) or 144 h (lane d). The lane de-
noted Control represents a positive control for 100% telomerase ac-
tivity to which no Antennapedia peptide was added. The lane de-
noted Lysis bu¡er represents a negative control to which no cell
extract was added. The lane denoted +RNase represents a negative
control containing the cell extract pretreated with RNase. The loca-
tion of the internal ampli¢cation standard (ITAS) is noted.
Fig. 6. Telomerase activity of JR8 growing cells after exposure to
25 or 50 WM of the biotinylated 13-mer PNA for 144 h. The loca-
tion of the internal ampli¢cation standard (ITAS) is noted.
Fig. 7. Telomere length of JR8 cells as determined by Southern blot
hybridization. Cells were exposed to di¡erent concentrations of the
cell-penetrating PNA construct for 144 h.
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